A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma

For the phase 1b part of the trial, participants must have advanced refractory solid tumors in any line of therapy. For the phase 2 part of the trial, participants must have recurrent or refractory NSCLC or HCC with elevated alpha-fetoprotein (AFP), or glioblastoma tumor type

Participants with NSCLC prior lines of therapy must include a platinum-based therapy

Participants with NSCLC must have completed neo-adjuvant or adjuvant therapy with a platinum doublet and have experienced disease recurrence within 6 months of completing the platinum doublet

Participants with HCC must have Child-Pugh A only

Participants with HCC must have had: one prior line of therapy which included sorafenib or have progressed or if not eligible for transarterial chemoembolization, were intolerant to sorafenib

Participants with HCC may have had sorafenib for locally advanced disease or are intolerant to sorafenib. Participants may have had clinical progression only following sorafenib or local therapy

Participants with Glioblastoma (GB) must have had previous first line of therapy with at least radiotherapy and temozolomide except for participants with O6-methylguanine-DNA methyltransferase (MGMT) unmethylated newly diagnosed GB

Participants with MGMT unmethylated newly diagnosed GB may have received radiation therapy only

Any participant must have adequate organ function

Any participant must use an approved contraceptive method

Any participant must not have moderate or severe cardiovascular disease